MedPath

Yokohama Heart Failure Investigators:Time Zone Dynamics of Serum Arginine-Vasopressin and Urine Aquaporin-2 on Acute Decompensated Heart Failure in the Patients with Depressed Left Ventricular Functio

Not Applicable
Recruiting
Conditions
Acute congestive heart failure
Registration Number
JPRN-UMIN000018717
Lead Sponsor
ational Hospital Organization Yokohama Medical Center
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
16
Inclusion Criteria

Not provided

Exclusion Criteria

1)patient with acute heart failure presenting clinical scenarios 3, 4, and 5 2)patient to whom tolvaptan has already been administered 3)patient to whom continuous intravenous infusion inotropes (catecholamine, phosphodiesterase-3 inhibitors, colforsin daropate hydrochloride, etc) has already been administered or is planned to be administered 4)patient who has received mechanical support (invasive mechanical ventilation, intraaortic balloon pumping, percutaneous cardiopulmonary support, continuation hemofiltration-dialysis, etc.) or is planned to use it 5)patient who presents shock at enrollment 6)Patient with advanced renal dysfunction (eGFR<30ml/min/1.73m2) 7)patient who is judged to be improper by the doctor in charge

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
urine volume per 6 hours
Secondary Outcome Measures
NameTimeMethod
Relationship between urine AQP2, serume AVP and diuresis effect of tolvaptan
© Copyright 2025. All Rights Reserved by MedPath